Document:

EXHIBIT 10.43

 

THIRD AMENDMENT TO

EMPLOYMENT AGREEMENT

 

Derma Sciences, Inc. (“Employer”),
and Frederic Eigner (“Employee”) are parties to an Employment Agreement dated March 12, 2012, as amended by First Amendment
dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the “Agreement”).

 

WHEREAS, Employer
and Employee desire to amend the Agreement to extend the Term for a period of two years and incorporate the Employer’s Claw
Back Policy, effective as of March 9, 2015 (the “Effective Date”).

 

WHEREAS, Employer
and Employee agree to amend the Employment Agreement as follows:

 

1.          Section
5 of the Agreement (entitled “Term”) is amended by deleting the date “March 31, 2015” and substituting
the date “March 31, 2017”. 

 

2.          Section
9 of the Agreement (originally Section 10 entitled “Clawback of Bonus and/or Incentive Compensation”) is amended by
deleting the existing language in its entirety and substituting the following in its place:

 

“Employee
understands that he is a Covered Person under, and agrees to comply with, the Derma Sciences, Inc. Claw Back Policy attached hereto
as Exhibit B, including consenting to any amendments to the Policy that may be made pursuant to the terms thereof.”

 

[Signatures on Following Page]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, this Agreement has
been executed by Employer and Employee as of the date first hereinabove written.

 

	 	EMPLOYER:
	 	 
	 	DERMA SCIENCES, INC.
	 	 	 
	 	By:	/s/ Edward J. Quilty
	 	 	Edward J. Quilty
	 	 	Chairman and Chief Executive Officer
	 	 	 
	 	EMPLOYEE:
	 	 	 
	 	By:	/s/ Frederic Eigner
	 	 	Frederic Eigner

 

    	2

    	 

    

 

EXHIBIT B

 

DERMA
SCIENCES, INC. 

 

CLAW
BACK POLICY

 

FEBRUARY
2015

 

If Derma Sciences, Inc. ("Derma”) is required
to prepare an accounting restatement due to material noncompliance with any financial reporting requirement, all incentive compensation
paid or credited to a Covered Person (as herein defined) for the restated period (not to exceed three years prior to the date such
restatement is required to be prepared) will be recalculated based on the restated results. To the extent the recalculated incentive
compensation is less than the incentive compensation actually paid or credited to a Covered Person for that period, the excess
amount must be forfeited or returned to Derma. As used in this Policy, the term "Covered Person" shall
mean each current or former Derma chief executive officer, executive vice president, senior vice president, named executive officer
or other employee designated in writing by Derma’s chief executive officer or chief financial officer.

 

In addition, if any Covered Person engaged in intentional misconduct
that contributed to an erroneous measure of Derma’s financial results, then whether or not an accounting restatement is then
required, all incentive compensation paid or credited to that Covered Person for the affected period will be recalculated based
on the corrected results. To the extent the recalculated incentive compensation is less than the incentive compensation actually
paid or credited to the Covered Person for that period, the excess amount must be forfeited or returned to Derma.

 

The objective of this policy is to reverse, to the maximum
extent possible, the improper economic benefit resulting from erroneous financial data (the "Excess Benefit").
Accordingly, each Covered Person affected by this policy shall forfeit and be required to repay to Derma any Excess Benefit.

 

In addition to the forfeiture of amounts earned but unpaid
and the repayment of cash amounts previously received, a Covered Person may be required to return shares of Derma stock previously
issued. If such issued shares have already been sold or otherwise transferred by the Covered Person, he or she will be required
to repay to Derma an amount equal to the greater of the then current value of such shares or the amount realized by the Covered
Person upon the sale or other transfer of those shares. All repayments will be based on the gross (i.e., pre-tax) amount
of the Excess Benefit.

 

In lieu of the actual repayment, Derma is authorized to offset the
amount of any Excess Benefit from any compensation then owed, or other obligation it or its affiliates then has, to a Covered Person.
In all cases, the amount required to be forfeited, repaid or offset will be determined by the Compensation Committee, in its sole
discretion.

 

    	3EXHIBIT 10.44

 

 

 

EMPLOYMENT AGREEMENT

 

THIS AGREEMENT,
made effective the 9th day of March, 2015 by and between Derma Sciences, Inc., a business corporation organized under the laws
of the State of Delaware (“Employer”), and John Caminis, M.D. (“Employee”).

 

WHEREAS, Employee
is to be employed by Derma Sciences as its Chief Medical Officer,

 

NOW, THEREFORE,
the parties hereto, in consideration of the mutual promises and covenants herein contained, hereby agree as follows:

 

1.          Employment.
Employer hereby employs Employee, and Employee agrees to be employed by Employer, as Employer’s Chief Medical Officer with
such duties appropriate to his office as may be assigned, from time to time, by the Chairman and Chief Executive Officer of Employer
and upon the terms and conditions hereinbelow set forth. Employee’s estimated date of commencement of employment is March
9, 2015.

 

2.          Time
and Efforts. Employee will devote substantially all of his business time and efforts to his duties hereunder.

 

3.          Compensation.
During the Term hereof Employer shall pay compensation to Employee as follows:

 

(a) Base compensation at the rate
of $325,000;

 

(b) A signing bonus of $50,000
payable with the first payroll after commencement of employment;

 

    	 

    	 

    

 

(c) an annual cash bonus as determined
by the Board of Directors. For 2015, Employee’s target bonus shall be 30% of Base compensation;

 

(d) Options to purchase 15,000
shares of Derma Sciences’ Common Stock (“Stock Options”) to vest in four (4) equal annual installments commencing
one year from date of commencement of employment;

 

(e) 15,000 Stock Options to vest
based on performance criteria as outlined on Exhibit A hereto;

 

(f) 5,000 Restricted
Share Units to vest based on performance criteria as outlined on Exhibit A hereto.

 

Sections 3(d)–(f)
represent the total equity-based compensation for Employee for 2015. Reviews by the compensation committee of Employee’s
base compensation and incentive compensation shall be undertaken not less often than annually. The principal criteria utilized
by the compensation committee in the conduct of its reviews shall be the extent to which Employer attains its performance objectives
and the extent of Employee’s contributions thereto.

 

5.          Term.
This Agreement shall be effective as of the date hereof and shall expire two years from the effective date of this Agreement unless
sooner terminated pursuant to Section 6 hereinbelow or unless renewed or extended by mutual agreement of the parties hereto.

 

6.          Severance.
In the event that Employer, without cause, either terminates the Employment of Employee or fails to renew this Agreement upon expiration
hereof, Employer shall pay to Employee severance compensation in an amount equal to one year of Employee’s annual rate of
base compensation as in effect immediately prior to such termination or expiration, as applicable. The severance shall be paid
in twelve equal monthly installments commencing on the first day of the month following the date of termination or expiration,
as applicable. In addition, during the twelve month period following the date of termination or expiration, as applicable, Employer
shall provide Employee with the same health care benefits provided by Employer to its active employees at the Employer’s
cost.

 

    	2

    	 

    

 

7.          Taxation.
Any payments made pursuant to this Agreement shall be subject to any tax or similar withholding requirements under applicable federal,
state or local employment or income tax laws or similar statutes or other provisions of law then in effect. This Agreement is intended
to comply with the requirements of Section 409A of the Internal Revenue Code and the regulations thereunder (“Section 409A”).
To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be
interpreted in a manner so that no payment due to Employee hereunder shall be deemed subject to an “additional tax”
within the meaning of Section 409A(a)(1)(B) of the Code. For purposes of Section 409A, each payment made under this Agreement shall
be treated as a separate payment. In addition, the right to a series of installment payments under this Agreement is to be treated
as a right to a series of separate payments. Notwithstanding anything contained herein to the contrary, Employer shall not be considered
to have terminated employment with Employer purposes of this Agreement unless Employee has incurred a “termination of employment”
from the Company within the meaning of Treasury Regulation §l.409A-l(h)(l)(ii) promulgated under Section 409A. Notwithstanding
the foregoing, if applicable and necessary to comply with the restriction in Section 409A(a)(2)(B) of the Code concerning payments
to “specified employees,” any payment made to Employee pursuant to this Agreement on account of the Employee’s
separation from service that would otherwise be due hereunder within six months after such separation from service shall nonetheless
be delayed until the first business day of the seventh month following Employee’s separation from service (or, if earlier,
the date of his death). The first payment that can be made to Employee following such period shall include the cumulative amount
of any payments or benefits that could not be paid or provided during such period due to the application of Code Section 409A(a)(2)(B)(i).
In no event may Employee, directly or indirectly, designate the calendar year of any payment. All reimbursements provided under
this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the
requirement that (i) any reimbursement is for expenses incurred during Employee’s lifetime (or during a shorter period of
time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect
the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made
on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement
is not subject to liquidation or exchange for another benefit. Employee further acknowledges that, while this Agreement is intended
to comply with Section 409A, any tax liability incurred by Employee under Section 409A is solely the responsibility of Employee.

 

    	3

    	 

    

 

8.          Option
Exercise Extension. In the event that Employer, without cause, either terminates Employee’s employment or fails to renew
this Agreement upon expiration hereof, then the period to exercise any option to purchase the securities of Employer of which Employee
may be possessed shall be extended to the earlier to occur of (i) the expiration thereof as set forth in the option instrument
or (ii) the 10th anniversary of the original date of grant.

 

9.          Claw
Back of Bonus and/or Incentive Compensation. Employee understands that he is a Covered Person under, and agrees to comply with,
the Derma Sciences, Inc. Claw Back Policy attached hereto as Exhibit B, including consenting to any amendments to the Policy that
may be made pursuant to the terms thereof.

 

    	4

    	 

    

 

10.         Release.
Notwithstanding anything to the contrary in this Agreement, Employer shall have no obligation to pay or provide any benefits
to Employee under Sections 6 or 8 of this Agreement unless and until Employee timely executes a waiver and release of claims in
a form provided by Employer (the “Release”) and the Release has become effective and irrevocable in accordance with
its terms. In the event a payment of benefit is subject to Employee’s execution and delivery of a Release, (a) Employer shall
deliver the Release to Employee within ten (10) business days following the date of termination, and Employer’s failure to
deliver a Release prior to the expiration of such ten (10) day period shall constitute a waiver of any requirement to execute a
Release; (b) if Employee fails to execute a Release on or prior to the Release Delivery Deadline (as defined below) or timely revokes
his acceptance of the Release thereafter, Employee shall not be entitled to any payments or benefits otherwise conditioned on the
Release; and (c) in any case where the date of termination and the Release Effectiveness Deadline (as defined below) fall in two
separate calendar years, any payments required to be made to Employee that are conditioned on the Release and are treated as non-qualified
deferred compensation for purposes of Section 409A shall commence in the later calendar year. For the purposes of this Section
10, “Release Delivery Deadline” shall mean the date that is twenty-one (21) calendar days following the date upon which
Employer timely delivers the Release to Employee, or, in the event that Employee’s termination of employment is “in
connection with an exit incentive or other employment termination program” (as such term is defined in the Age Discrimination
in Employment Act of 1967), the date that is forty-five (45) calendar days following such delivery date. For purposes of this Section
10, “Release Effectiveness Deadline” shall mean the date that is seven (7) calendar days following the Release Delivery
Deadline. Except as otherwise provided in Section 7 hereof, the extent that any payments of benefits due under this Agreement are
delayed pursuant to this Section 10, such amounts shall be paid in a lump sum (without interest) on the first payroll date following
the date that the Release becomes effective and irrevocable in accordance with its terms or, in the case of any payments subject
to Section 10(c) above, on the first payroll period to occur in the subsequent calendar year, if later.

 

    	5

    	 

    

 

11. Benefits. Employee shall
be entitled to PTO (Paid Time-Off) at an accrual of 20 days per year and up to 6 paid sick days per year. Employee shall be entitled
to receive medical, dental and other employee benefits as are currently offered and may in the future be offered to similarly situated
employees by the Company. Such benefits currently include eligibility for Medical, Dental, Vision, Life & AD&D, LTD and
eligibility for the Company’s 401(k) Plan after 90 days of employment. These benefits may be modified or discontinued by
the Company at any time.

 

IN WITNESS WHEREOF,
this Agreement has been executed by Employer and Employee as of the date first hereinabove written.

 

	 	EMPLOYER:
	 	 
	 	DERMA SCIENCES, INC.
	 	 	 
	 	By:	/s/ Edward J. Quilty
	 	 	Edward J. Quilty
	 	 	Chairman and Chief Executive Officer
	 	 
	 	EMPLOYEE:
	 	 	 
	 	By:	/s/ John Caminis
	 	 	John Caminis, M.D.

 

    	6

    	 

    

 

Exhibit A

 

Option Vesting

 

For the Stock Options set forth in paragraph
3(e) and the Restricted Share Units set forth in Section 3(f):

 

(a) 75% of such Stock Options and Restricted
Share Units shall vest at such time as the Phase III DSC-127 clinical trials (Stride 1 and Stride 2) have achieved 100% enrollment,
provided 100% enrollment is achieved on or before December 31, 2015. If less than 100% enrollment is achieved on or before December
31, 2015, partial vesting will be determined by the Compensation Committee.

 

(b) 25% vested upon completion of other
scheduled clinical trials as determined by the Compensation Committee.

 

    	7

    	 

    

 

Exhibit B

 

Claw Back Policy

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]